Seyed Ali Sajadian , Nadia Esfandiari , Luis Padrela
{"title":"利用二氧化碳作为气体反溶剂生产格列本脲纳米颗粒、格列本脲-HPMC 和格列本脲-PVP 复合材料","authors":"Seyed Ali Sajadian , Nadia Esfandiari , Luis Padrela","doi":"10.1016/j.jcou.2024.102832","DOIUrl":null,"url":null,"abstract":"<div><p>Glibenclamide is an antidiabetic drug that also acts as an anti-inflammatory factor and reduces oxidative stress, medullary edema, and heart attack. Glibenclamide has high permeability and poor solubility in water (BCS class II). This work addresses particle size reduction of Glibenclamide using the gas antisolvent (GAS) to improve the drug dissolution rate. Three process parameters were studied at three levels: pressure (120, 140, and 160 bar), temperature (308, 318, and 328 K), and initial solute concentration (15, 45, and 75 mg/mL). The Box-Behnken design method was applied to optimize the process conditions. The coprecipitation of Glibenclamide with polyvinyl pyrrolidone (PVP) and hydroxypropyl methylcellulose (HPMC) was investigated by GAS at optimum pressure and temperature conditions (i.e., 160 bar and 308 K). Furthermore, the particles produced were characterized by high performance liquid chromatography, powder x-ray diffraction, differential scanning calorimetry, Fourier transform infrared spectrometry, dynamic light scattering, and field emission scanning electron microscopy. The maximum dissolution rate in water obtained after 75 minutes was 36.6 %, 88.3 %, 94.1 %, and 97.7 % for unprocessed Glibenclamide, Glibenclamide nanoparticles, Glibenclamide-HPMC and Glibenclamide-PVP composites, respectively. Glibenclamide-HPMC nanocomposites produced by GAS showed the smallest particle size, while Glibenclamide-HPMC exhibited the fastest dissolution rate.</p></div>","PeriodicalId":350,"journal":{"name":"Journal of CO2 Utilization","volume":null,"pages":null},"PeriodicalIF":7.2000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2212982024001677/pdfft?md5=b52423eabb25543c78992cdb6faefede&pid=1-s2.0-S2212982024001677-main.pdf","citationCount":"0","resultStr":"{\"title\":\"CO2 utilization as a gas antisolvent in the production of glibenclamide nanoparticles, glibenclamide-HPMC, and glibenclamide-PVP composites\",\"authors\":\"Seyed Ali Sajadian , Nadia Esfandiari , Luis Padrela\",\"doi\":\"10.1016/j.jcou.2024.102832\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Glibenclamide is an antidiabetic drug that also acts as an anti-inflammatory factor and reduces oxidative stress, medullary edema, and heart attack. Glibenclamide has high permeability and poor solubility in water (BCS class II). This work addresses particle size reduction of Glibenclamide using the gas antisolvent (GAS) to improve the drug dissolution rate. Three process parameters were studied at three levels: pressure (120, 140, and 160 bar), temperature (308, 318, and 328 K), and initial solute concentration (15, 45, and 75 mg/mL). The Box-Behnken design method was applied to optimize the process conditions. The coprecipitation of Glibenclamide with polyvinyl pyrrolidone (PVP) and hydroxypropyl methylcellulose (HPMC) was investigated by GAS at optimum pressure and temperature conditions (i.e., 160 bar and 308 K). Furthermore, the particles produced were characterized by high performance liquid chromatography, powder x-ray diffraction, differential scanning calorimetry, Fourier transform infrared spectrometry, dynamic light scattering, and field emission scanning electron microscopy. The maximum dissolution rate in water obtained after 75 minutes was 36.6 %, 88.3 %, 94.1 %, and 97.7 % for unprocessed Glibenclamide, Glibenclamide nanoparticles, Glibenclamide-HPMC and Glibenclamide-PVP composites, respectively. Glibenclamide-HPMC nanocomposites produced by GAS showed the smallest particle size, while Glibenclamide-HPMC exhibited the fastest dissolution rate.</p></div>\",\"PeriodicalId\":350,\"journal\":{\"name\":\"Journal of CO2 Utilization\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":7.2000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2212982024001677/pdfft?md5=b52423eabb25543c78992cdb6faefede&pid=1-s2.0-S2212982024001677-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of CO2 Utilization\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2212982024001677\",\"RegionNum\":2,\"RegionCategory\":\"工程技术\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of CO2 Utilization","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212982024001677","RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
摘要
格列本脲是一种抗糖尿病药物,同时也是一种抗炎因子,可减少氧化应激、延髓水肿和心脏病发作。格列本脲在水中具有高渗透性和低溶解性(BCS II 级)。本研究利用气体抗溶剂(GAS)降低格列本脲的粒度,以提高药物溶解率。研究了三个级别的工艺参数:压力(120、140 和 160 巴)、温度(308、318 和 328 K)和初始溶质浓度(15、45 和 75 毫克/毫升)。采用方框-贝肯设计法对工艺条件进行了优化。在最佳压力和温度条件下(即 160 巴和 308 K),通过 GAS 研究了格列本脲与聚乙烯吡咯烷酮(PVP)和羟丙基甲基纤维素(HPMC)的共沉淀。此外,还利用高效液相色谱法、粉末 X 射线衍射法、差示扫描量热法、傅立叶变换红外光谱法、动态光散射法和场发射扫描电子显微镜对所制备的颗粒进行了表征。75 分钟后,未加工的格列本脲、格列本脲纳米颗粒、格列本脲-HPMC 和格列本脲-PVP 复合材料在水中的最大溶解度分别为 36.6%、88.3%、94.1% 和 97.7%。用 GAS 生产的格列本脲-HPMC 纳米复合材料的粒径最小,而格列本脲-HPMC 的溶解速度最快。
CO2 utilization as a gas antisolvent in the production of glibenclamide nanoparticles, glibenclamide-HPMC, and glibenclamide-PVP composites
Glibenclamide is an antidiabetic drug that also acts as an anti-inflammatory factor and reduces oxidative stress, medullary edema, and heart attack. Glibenclamide has high permeability and poor solubility in water (BCS class II). This work addresses particle size reduction of Glibenclamide using the gas antisolvent (GAS) to improve the drug dissolution rate. Three process parameters were studied at three levels: pressure (120, 140, and 160 bar), temperature (308, 318, and 328 K), and initial solute concentration (15, 45, and 75 mg/mL). The Box-Behnken design method was applied to optimize the process conditions. The coprecipitation of Glibenclamide with polyvinyl pyrrolidone (PVP) and hydroxypropyl methylcellulose (HPMC) was investigated by GAS at optimum pressure and temperature conditions (i.e., 160 bar and 308 K). Furthermore, the particles produced were characterized by high performance liquid chromatography, powder x-ray diffraction, differential scanning calorimetry, Fourier transform infrared spectrometry, dynamic light scattering, and field emission scanning electron microscopy. The maximum dissolution rate in water obtained after 75 minutes was 36.6 %, 88.3 %, 94.1 %, and 97.7 % for unprocessed Glibenclamide, Glibenclamide nanoparticles, Glibenclamide-HPMC and Glibenclamide-PVP composites, respectively. Glibenclamide-HPMC nanocomposites produced by GAS showed the smallest particle size, while Glibenclamide-HPMC exhibited the fastest dissolution rate.
期刊介绍:
The Journal of CO2 Utilization offers a single, multi-disciplinary, scholarly platform for the exchange of novel research in the field of CO2 re-use for scientists and engineers in chemicals, fuels and materials.
The emphasis is on the dissemination of leading-edge research from basic science to the development of new processes, technologies and applications.
The Journal of CO2 Utilization publishes original peer-reviewed research papers, reviews, and short communications, including experimental and theoretical work, and analytical models and simulations.